Clinical Trial

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-12-01; most recent amendment 2026-06-26.
Status change: Not Yet Recruiting → Recruiting 2026-01-26
Trial Details
NCT Number NCT07276373
Lead Sponsor Corcept Therapeutics
Conditions Neoplasms
Enrollment 50 participants
Start Date 2026-01-16
Primary Completion 2026-09 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-30